title: AE37: a novel T-cell-eliciting vaccine for breast cancer.
abstract: BACKGROUND
  Immunotherapy, including vaccines targeting the human EGFR2 (HER-2/neu) protein, is an active area of investigation in combatting breast cancer. Several vaccines are currently undergoing clinical trials, most of which are CD8(+) T-cell-eliciting vaccines. AE37 is a promising primarily CD4(+) T-cell-eliciting HER-2/neu breast cancer vaccine currently in clinical trials.
  
  
  METHODS
  This article reviews preclinical investigations as well as findings from completed and ongoing Phase I and Phase II clinical trials of the AE37 vaccine.
  
  
  CONCLUSIONS
  Clinical trials have shown the AE37 vaccine to be safe and capable of generating peptide-specific, durable immune responses. This has been shown in patients with any level of HER-2/neu expression. Early clinical findings suggest there may be benefit to AE37 vaccination in preventing breast cancer recurrence.
authors: Brooke Army Medical Center, Department of General Surgery, 3851 Roger Brooke Drive, Ft. Sam Houston, TX 78234, USA.
authors: Alan K
authors: AK
authors: Sears
authors: Sonia A
authors: SA
authors: Perez
authors: Guy T
authors: GT
authors: Clifton
authors: Linda C
authors: LC
authors: Benavides
authors: Jeremy D
authors: JD
authors: Gates
authors: Kevin S
authors: KS
authors: Clive
authors: Jarrod P
authors: JP
authors: Holmes
authors: Nathan M
authors: NM
authors: Shumway
authors: David C
authors: DC
authors: Van Echo
authors: Mark G
authors: MG
authors: Carmichael
authors: Sathibalan
authors: S
authors: Ponniah
authors: Constantin N
authors: CN
authors: Baxevanis
authors: Elizabeth A
authors: EA
authors: Mittendorf
authors: Michael
authors: M
authors: Papamichail
authors: George E
authors: GE
authors: Peoples
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D018719:Erb-b2 Receptor Tyrosine Kinases; C530655:AE37 vaccine; C508053:ERBB2 protein, human